Partnering for Innovation in Manufacturing & Supply

How are bio/pharma companies and their partners collaborating to resolve the difficult challenges that arise in development, manufacturing, and the supply chain? DCAT Member Companies are invited to apply to share fresh insights, best practices, and lessons learned at a DCAT Week program. Applications close January 13, 2025.

How are bio/pharma companies and their partners collaborating to resolve the difficult challenges that arise in development, manufacturing, and the supply chain? DCAT Member Companies are invited to apply to share fresh insights, best practices, and lessons learned at a DCAT Week program. Applications deadline extended and closes January 24, 2025.

By Patricia Van Arnum, Editorial Director, DCAT, pvanarnum@dcat.org

A solutions-based program at DCAT Week
Innovation is essential for achieving operational excellence and delivering value. A DCAT Week 2025 program, Partnering for Innovation in Manufacturing & Supply, will feature case studies on how bio/pharma companies and their partners have collaborated to resolve the hard challenges that arise in development, manufacturing, and the supply chain. Partner companies include CDMOs/CMOs, suppliers of raw materials or other inputs, technology services providers, or other companies, including other bio/pharma companies.

The 90-minute program will consist of three co-presentations (20 minutes each) between a bio/pharma company and partner company. It is a way to share fresh insights, best practices, and lessons learned to a well-informed business audience of senior to mid-level executives.

DCAT Member Companies are invited to submit applications by January 24, 2025, for consideration of their case study.  A task force of industry colleagues selected from DCAT volunteer committees and leadership will evaluate all applications and select three case studies providing the most useful, valuable, and innovative insight of utility and interest to DCAT Member Companies. Presentations will be due March 3, 2025. Further information, including the online application to apply, may be found here.

Topics of interest
The case studies may address a range of topics—but must reflect an innovative or better approach taken in manufacturing or supply. Potential topics can include:

  • New technologies in drug-substance and drug-product manufacturing or packaging;
  • Cost optimization and improved production economics;
  • Collaborative project management;
  • Increasing supply-chain performance, resiliency, or visibility;
  • Upgraded inventory management;
  • Collaborative demand and supply planning/forecasting;
  • Sustainability improvements: technology, manufacturing & metrics;
  • Digitalization to better performance, including regulatory compliance; or
  • Other innovation in manufacturing and supply.

The program provides a way to stand out among your peers in the industry by showing  resourceful and effective ways to advance manufacturing and supply. Further information, including the online application to apply, may be found here.

Recent Feature Articles

New Drug Approvals in 2024: How Did The Industry Fare?

By
How did the industry fare with new drug approvals in 2023? What new drugs were approved by FDA and were approvals in pace with prior years? What was the mix between small molecules and biologics, and which companies and products made the mark? DCAT Value Chain Insights sums it up.

Have Your Company be A Newsmaker at DCAT Week

By
Applications are closing Wednesday February 5 for the DCAT Member Company Announcement Forum, a much-anticipated event at DCAT Week in which senior executives from DCAT Member Companies highlight major news announcements covering expansions, M&A, and other key strategic developments.

Industry Roundtable: Small-Molecule APIs

By
What are the key issues shaping the market for small-molecule drugs and related trends in manufacturing? An industry roundtable of senior executives share their perspectives on what is driving the market.

What Trending: Biologic-Based Drugs

By
What were the biologic-based drugs approved by FDA’s Center for Drug Evaluation and Research in 2024? Which companies and products crossed the regulatory finish line and how do they fit in the market?